Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what research is being commissioned by the NHS into potential treatments for long covid.

The Department funds research on health and social care through the National Institute for Health and Care Research (NIHR). Between 2019/20 and 2023/24, the NIHR and the Medical Research Council (MRC), part of UK Research and Innovation, have jointly invested over £57 million into long COVID research with the aim of improving diagnosis and our understanding of the underlying mechanisms of the disease, as well as evaluating the effectiveness of pharmacological and non-pharmacological therapies and interventions, and clinical care.

The NIHR has awarded funding to a number of projects and programmes investigating treatments for long COVID. These have included clinical trials to test and compare different treatments such as antihistamines, anticoagulants and anti-inflammatory medicines. The Rehabilitation Exercise and psycholoGical support After COVID-19 InfectioN (REGAIN) trial, funded by NIHR, provided the first high-quality evidence confirming the sustained clinical benefit and lack of harm with rehabilitation programmes for long COVID. The NIHR has also provided £1.1 million in funding towards the Listen trial, which found that participants who received the Listen self-management tool intervention had greater capacity for daily activities, improved mental health, reduced fatigue impact and increased self-efficacy. However, there is more work to be done to find the most promising treatments and interventions, and we are actively exploring next steps for long COVID research.

Together with MRC, we have created a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical inventions for post-acute infection syndromes and associated conditions, including long COVID. We are also planning a showcase event, hosted by NIHR and MRC, for the research of post-acute infection conditions, including myalgic encephalomyelitis/chronic fatigue syndrome and long COVID, later this year to stimulate further research in this field.